US equities |
MU $1,038.88 ▼-4.51% NVDA $230.31 ▼-3.02% SNDK $1,604.69 ▼-5.18% AMD $617.19 ▼-4.44% INTC $105.84 ▼-6.43% SPCX $161.73 ▼-3.50% META $715.89 ▼-0.75% PLTR $196.10 ▲+1.02%
FinancialContent

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

9.255 -0.235 (-2.48%)
Delayed Quote Updated: 1:55 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immix Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study ↗
Immix Biopharma (NASDAQ:IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a... 
Via MarketBeat
News headline image
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – 
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
From Pomerantz LLP
Via GlobeNewswire
News headline image
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
From Holzer & Holzer
Via GlobeNewswire
News headline image
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in Upcoming Investor Conferences
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities ↗
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement. 
Via Benzinga
News headline image
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗
Market-based odds now show an 87% chance of a rate cut. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >